Giovanni Luca Cipriano

Mr. Giovanni Luca Cipriano

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GCGiovanni Luca Cipriano
Giovanni Luca Cipriano
SGSchepici Giovanni
Schepici Giovanni
EMEmanuela Mazzon
Emanuela Mazzon
IAIvan Anchesi
Ivan Anchesi
Multiple sclerosis (MS) is a degenerative condition characterized by axonal damage and demyelination induced by autoreactive immune cells that occur in the Central Nervous System (CNS). The interaction between epigenetic changes and genetic factors can be widely involved in the onset, development, and progression of the disease. Although numerous efforts were made to discover new therapies able to prevent and improve the course of MS, definitive curative treatments have not been found yet. However, in recent years, it has been reported that non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long ncRNAs (lncRNAs), and circular RNAs (circRNAs), acting as gene expression regulators, could be used as potential therapeutic targets or biomarkers to diagnose and fight MS. In this review, we discussed the role of miRNAs, lncRNAs, and circRNAs, as well as their expression level changes and signaling pathways that are related to preclinical and human MS studies. Hence, the investigation of ncRNAs could be important to provide additional information regarding MS pathogenesis as well as promote the discovery of new therapeutic strategies or biomarkers.

Verified
Journal Article
Open access
PDF file
GCGiovanni Luca Cipriano
Giovanni Luca Cipriano
EMEmanuela Mazzon
Emanuela Mazzon
IAIvan Anchesi
Ivan Anchesi
Alzheimer’s disease (AD) is a long-term neurodegenerative condition that leads to the deterioration of neurons and synapses in the cerebral cortex, resulting in severe dementia. AD is significantly more prevalent in postmenopausal women, suggesting a neuroprotective role for estrogen. Estrogen is now known to regulate a wide array of physiological functions in the body by interacting with three known estrogen receptors (ERs) and with the β-amyloid precursor protein, a key factor in AD pathogenesis. Recent experimental evidence indicates that new selective ER modulators and phytoestrogens may be promising treatments for AD for their neuroprotective and anti-apoptotic properties. These alternatives may offer fewer side effects compared to traditional hormone therapies, which are associated with risks such as cardiovascular diseases, cancer, and metabolic dysfunctions. This review sheds light on estrogen-based treatments that may help to partially prevent or control the neurodegenerative processes characteristic of AD, paving the way for further investigation in the development of estrogen-based treatments.

25 June 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
IRIvana Raffaele
Ivana Raffaele
GCGiovanni Luca Cipriano
Giovanni Luca Cipriano
IAIvan Anchesi
Ivan Anchesi
SOSalvatore Oddo
Salvatore Oddo
SSSerena Silvestro
Serena Silvestro
Alzheimer’s disease (AD), the leading cause of dementia, remains poorly understood despite decades of intensive research, which continues to hinder the development of effective treatments. As a complex multifactorial disorder, AD lacks a cure to halt the progressive neurodegeneration, and the precise mechanisms underlying its onset and progression remain elusive, limiting therapeutic options. Due to the challenges of studying neuronal cells in vivo, technologies such as clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9) and human-induced pluripotent stem cells (hiPSCs) are key for identifying therapeutic targets, although they face technical and ethical hurdles in their early stages. CRISPR/Cas9 and hiPSCs are promising for disease modeling and therapy, but off-target effects and the complexity of gene editing in the brain limit their use. CRISPR technology enables specific genetic modifications in key AD-related genes, such as APP, PSEN1, PSEN2, and APOE, providing valuable insights into disease mechanisms. iPSC-derived neurons, astrocytes, microglia, and 3D organoids can recapitulate key aspects of human AD pathology, but they do not fully replicate the complexity of the human brain, limiting clinical applicability. These technologies advance studies of amyloid processing, tau aggregation, neuroinflammation, and oxidative stress, yet translating them into clinical therapies remains challenging. Despite the promise of CRISPR/Cas9 and iPSCs for precision medicine, gaps in knowledge about their long-term safety and efficacy must be addressed before clinical implementation.

Verified
Journal Article
Open access
PDF file
OAOsvaldo Artimagnella
Osvaldo Artimagnella
AFAlessia Floramo
Alessia Floramo
GCGiovanni Luca Cipriano
Giovanni Luca Cipriano
VAVeronica Argento
Veronica Argento
MLMaria Lui
Maria Lui
The SH-SY5Y cell line is widely used as an in vitro model for pharmacological and molecular investigations of Parkinson’s disease (PD). The use of SH-SY5Y cells in PD research critically relies on their ability to differentiate into a mature, post-mitotic, dopaminergic (DAergic) neuronal phenotype. However, SH-SY5Y cells are inherently heterogeneous since they are firstly catecholaminergic cells and may express diverse phenotypic markers besides the DAergic ones. These properties seem to be determined by the differentiation protocol that is employed, thus meaning it is crucial to obtain proper cell types. This systematic review aims to discuss the main differentiation protocols used in PD research over the last 30 years. They include inducers such as retinoic acid (RA), the phorbol ester TPA, and the BDNF. Among the 514 studies that were screened, 249 employed these inducers. Then, we quantitatively report the ability of these protocols to differentiate SH-SY5Y cells in mature DAergic neurons, evaluating morphology, differentiation markers, and DAergic markers among the studies that specifically compared differentiated to undifferentiated SH-SY5Y cells (61 studies over 249). As our research shows, despite the highest usage of the RA differentiation protocol, the combination of RA with the BDNF inducer seems to increase the expression and the acquisition of a DAergic phenotype. Nevertheless, during this analysis, some limitations emerged, highlighting the intrinsic phenotypic heterogeneity of these cells, thereby limiting their suitability according to the specific biological question under investigation. A deep investigation into the literature about the molecular phenotypic features of differentiated SH-SY5Y cells may eventually help us to understand the advantages and disadvantages of each protocol that was employed, and adequately set experiments around the PD research.

Verified
Journal Article
Open access
PDF file
GCGiovanni Luca Cipriano
Giovanni Luca Cipriano
IRIvana Raffaele
Ivana Raffaele
AFAlessia Floramo
Alessia Floramo
VAVeronica Argento
Veronica Argento
DDDeborah Stefania Donato
Deborah Stefania Donato
IAIvan Anchesi
Ivan Anchesi
Hericium erinaceus (H. erinaceus), a medicinal mushroom, is a source of bioactive compounds with demonstrated neuroprotective potential. This activity is primarily attributed to two distinct classes of compounds: erinacines from the mycelium, which potently induce the synthesis of neurotrophins, protein growth factors essential for neuronal survival and health, and hericenones from the fruiting body, which subsequently appear to enhance or potentiate neurotrophin-activated signaling pathways. Preclinical evidence substantiates their ability to enhance neurotrophin levels, particularly Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF), and activate their cognate Trk receptors. Activation of these pathways, including PI3K/AKT/mTOR and MAPK/ERK, converges on transcription factors such as CREB, promoting neuronal survival, neurite outgrowth, and synaptic plasticity. However, the precise molecular mechanisms linking these small molecules to the complex orchestration of neurotrophic gene expression remain incompletely defined. This review synthesizes current knowledge of the neurotrophic pharmacology of H. erinaceus bioactives and proposes a novel framework suggesting that non-coding RNAs (ncRNAs) play a key regulatory role. We hypothesize that hericenones and erinacines modulate key transcriptional hubs, such as CREB, Nrf2, and NF-κB, which in turn regulate the expression of specific ncRNAs (e.g., miR-132, miR-146a) known to control neurogenesis, synaptogenesis, oxidative stress, and neuroinflammation. This ncRNA-mediated mechanism may represent an un-explored axis that explains the pleiotropic neuroprotective effects of these compounds. We critically appraise the existing preclinical evidence, identify significant methodological limitations and translational gaps, and propose a structured research roadmap to test these ncRNA-centric hypotheses, aiming to accelerate the rational development of H. erinaceus-derived compounds for neurodegenerative diseases.

26 November 2025 in Cells
Verified
Journal Article
Open access
PDF file
IAIvan Anchesi
Ivan Anchesi
Maria Francesca AstorinoMaria Francesca Astorino
Maria Francesca Astorino
IRIvana Raffaele
Ivana Raffaele
DDDeborah Stefania Donato
Deborah Stefania Donato
SSSerena Silvestro
Serena Silvestro
GCGiovanni Luca Cipriano
Giovanni Luca Cipriano
Multiple Sclerosis (MS) therapies effectively modulate peripheral immune responses but largely fail to promote neural repair within the central nervous system. This review evaluates whether psychedelic compounds (PSYs), via 5-HT2A activation, can fill a critical therapeutic gap: the need for agents that simultaneously suppress neuroinflammation and promote regeneration. We dissect the evidence suggesting PSYs can reprogram the neuroimmune milieu by downregulating key pro-inflammatory cytokines (e.g., TNF-α, IL-6) in glial cells while concurrently upregulating crucial neurotrophic factors (e.g., BDNF) that promote synaptic plasticity and oligodendrocyte support. However, we argue that the current evidence, largely derived from non-specific inflammation models, is insufficient to predict clinical efficacy in an autoimmune disease like MS. We critically analyze the significant translational barriers—from cardiovascular and psychiatric risks to profound legal and ethical challenges—that temper the immediate clinical promise. Finally, we propose a forward-looking perspective, suggesting that the true value of PSYs may lie not in their direct clinical use, but in uncovering novel therapeutic pathways. The emergence of non-hallucinogenic, functionally selective 5-HT2A agonists, inspired by psychedelic pharmacology, represents a more viable strategy to harness these mechanisms for MS therapy, demanding rigorous preclinical validation in disease-relevant models.